Internal Medicine · Warner Robins, GA
NPI
1578519286
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
3
Medicare group memberships
Hospitals
4
Hospital affiliations
2054 Watson Blvd
Warner Robins, GA, 31093
Phone (478) 918-0770
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.1M
36,785 services
Medicare patients, 2024
1,911
Average age 73
Drug cost, 2024
$3.8M
35,541 prescriptions
Company payments, 2025
$3,240
From 36 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mohammad N Al Shroof was code J1071 (injection, testosterone cypionate, 1 mg), 12,951 times for 11 patients. In total Mohammad N Al Shroof billed 36,785 services in 85 codes, and Medicare paid $1.1M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-05-10.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1071 Injection, testosterone cypionate, 1 mg | Office | 12,951 | 11 | $0.02 | $219 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 3,489 | 985 | $11.87 | $41K |
| 99214 Office E&M - Established | Office | 2,894 | 1,002 | $89.26 | $258K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 1,691 | 304 | $44.72 | $76K |
| 99213 Office E&M - Established | Office | 1,665 | 672 | $62.78 | $105K |
| 99457 E&M - Miscellaneous | Office | 1,354 | 230 | $34.98 | $47K |
| 99309 SNF E&M | Office | 1,263 | 251 | $80.30 | $101K |
| 99454 E&M - Miscellaneous | Office | 884 | 157 | $32.44 | $29K |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 848 | 242 | $34.90 | $30K |
| G0444 Annual depression screening, 5 to 15 minutes | Office | 762 | 708 | $17.16 | $13K |
| 99211 Office E&M - Established | Office | 704 | 406 | $14.87 | $10K |
| 99497 Care Management/Coordination | Office | 693 | 687 | $71.89 | $50K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 642 | 127 | $0.09 | $54.79 |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 641 | 641 | $109.43 | $70K |
| 99489 Chronic, Principal, and Transitional Care Management | Office | 630 | 172 | $52.97 | $33K |
By year: 2022 $1.3M for 51,155 services; 2023 $1.0M for 46,168 services; 2024 $1.1M for 36,785 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81002 Clinical Chemistry | 148 | 112 | $3.39 | $501 |
| 87804 Immunoassay | 89 | 47 | $16.22 | $1,444 |
| 80305 Drug Tests | 86 | 72 | $12.12 | $1,043 |
| 82043 Clinical Chemistry | 84 | 83 | $5.66 | $475 |
| 87426 Immunoassay | 70 | 61 | $34.13 | $2,389 |
| 82962 Clinical Chemistry | 22 | 22 | $3.21 | $70.62 |
| 36415 Venipuncture Blood Collection | 15 | 12 | $8.07 | $121 |
Medicare prescription drug claims, 2024
In 2024, the drug Mohammad N Al Shroof prescribed most often to Medicare patients was Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen), with 1,656 prescriptions and refills. In total Mohammad N Al Shroof wrote 35,541 Medicare prescriptions that cost $3.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 1,656 | 1,656 | 306 | $37K |
| Atorvastatin Calcium Generic | 1,330 | 2,580 | 366 | $17K |
| Amlodipine Besylate Generic | 1,277 | 2,676 | 372 | $10K |
| Gabapentin Generic | 1,096 | 1,748 | 296 | $21K |
| Levothyroxine Sodium Generic | 1,040 | 2,174 | 281 | $13K |
| Losartan Potassium Generic | 912 | 2,038 | 292 | $9,409 |
| Metformin Hcl Generic | 672 | 1,481 | 212 | $5,940 |
| Lisinopril Generic | 619 | 1,431 | 182 | $5,415 |
| Furosemide Generic | 614 | 1,010 | 175 | $4,118 |
| Pantoprazole Sodium Generic | 589 | 1,188 | 194 | $6,871 |
| Eliquis Apixaban | 575 | 773 | 107 | $333K |
| Carvedilol Generic | 569 | 1,045 | 144 | $6,397 |
| Hydralazine Hcl Generic | 526 | 894 | 142 | $8,753 |
| Simvastatin Generic | 523 | 1,264 | 175 | $3,487 |
| Rosuvastatin Calcium Generic | 444 | 1,003 | 135 | $8,599 |
Brand drugs: 5,207 claims; generic drugs: 30,094 claims; opioid claims: 2,533.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mohammad N Al Shroof $3,240 ($3,240 in general payments such as food, travel and fees) from 36 companies. The largest payer was Abbvie Inc. with $357.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 17 | $357 |
| Pfizer Inc. PFE | 20 | $354 |
| AstraZeneca Pharmaceuticals LP AZN | 14 | $266 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 11 | $238 |
| Novo Nordisk Inc NVO | 9 | $201 |
| Eisai Inc. 4523.T | 3 | $167 |
| Amgen Inc. AMGN | 11 | $145 |
| Lilly USA, LLC LLY | 11 | $143 |
| Beta Bionics, Inc. BBNX | 2 | $139 |
| Astellas Pharma US Inc 4503.T | 5 | $103 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.